RE: Triumeq
Well, for one, it has proven superiority to Atripla which no other fixed dose combination can claim. It does not have the renal problem that everything Viread-based does and TAF is now trying to fix. It does not need a booster like Stribild. The only drawback is the abacavir hypersensitivity which is very infrequent and can be tested for. In the right hands, and I don't know if ViiV is the right hands, this drug could finally break GILD's HIV dominance. The clinical parameters for success are there, it's just a matter of commercial execution.
Market Data 
Markets 
AI
